ImmunoGenesis
Dr. Christine Gagliardi joined ImmunoGenesis as Director, Research and Development, in December 2020 from Bellicum Pharmaceuticals, where she served as Director, Product Development. Other prior industry experience includes research and development roles at Pfizer and Progenitor Cell Therapy. Dr. Gagliardi received a Ph.D. in Biomedical Sciences/Pharmacology from Tulane University and a BS in Molecular, Cellular, and Developmental Biology from Yale University.
ImmunoGenesis
1 followers
ImmunoGenesis develops science-driven immune therapies specifically designed to treat tumors lacking activated T cells or having other immune resistance mechanisms.